Document Detail


Stereotactic body radiotherapy for oligometastases.
MedLine Citation:
PMID:  23276369     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The management of metastatic solid tumours has historically focused on systemic treatment given with palliative intent. However, radical surgical treatment of oligometastases is now common practice in some settings. The development of stereotactic body radiotherapy (SBRT), building on improvements in delivery achieved by intensity-modulated and image-guided radiotherapy, now allows delivery of ablative doses of radiation to extracranial sites. Many non-randomised studies have shown that SBRT for oligometastases is safe and effective, with local control rates of about 80%. Importantly, these studies also suggest that the natural history of the disease is changing, with 2-5 year progression-free survival of about 20%. Although complete cure might be possible in a few patients with oligometastases, the aim of SBRT in this setting is to achieve local control and delay progression, and thereby also postpone the need for further treatment. We review published work showing that SBRT offers durable local control and the potential for progression-free survival in non-liver, non-lung oligometastatic disease at a range of sites. However, to test whether SBRT really does improve progression-free survival, randomised trials will be essential.
Authors:
Alison C Tree; Vincent S Khoo; Rosalind A Eeles; Merina Ahmed; David P Dearnaley; Maria A Hawkins; Robert A Huddart; Christopher M Nutting; Peter J Ostler; Nicholas J van As
Related Documents :
24633759 - Factor associated with failure to administer subsequent treatment after progression in ...
23774619 - Mediastinal lymph-nodes metastasis beyond the lobe-specific: an independent risk factor...
23553849 - A multicenter phase ii study of ganetespib monotherapy in patients with genotypically d...
24135249 - Pleuropneumonectomy for diffuse pleural metastasis in primary lung cancer.
23882429 - An exceptional case of myelodysplastic syndrome with myelofibrosis following combinatio...
2369729 - Photodynamic therapy by topical meso-tetraphenylporphinesulfonate tetrasodium salt admi...
19770379 - Phase ii study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refracto...
23582479 - Eau guidelines on primary urethral carcinoma.
18615619 - Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The lancet oncology     Volume:  14     ISSN:  1474-5488     ISO Abbreviation:  Lancet Oncol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100957246     Medline TA:  Lancet Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  e28-37     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Affiliation:
Royal Marsden NHS Foundation Trust, London, UK. Electronic address: alison.tree@rmh.nhs.uk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular diagnostics in paediatric glial tumours.
Next Document:  The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategie...